Sidewinder Therapeutics is developing next-generation bispecific ADCs designed to expand the therapeutic window through enhanced tumor specificity and internalization. The company has partnered with Lonza to apply Synaffix's site-specific linker-payload platform across multiple programs. Founded in 2023 with OrbiMed, Sidewinder is headquartered in San Diego and has raised a total of $162 million from a world-class investor syndicate.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/08/26	$137,000,000	Series B	Alexandria Venture Investments Astellas Venture Management DCVC Frazier Life Sciences Goldman Sachs Longwood Fund Novartis Venture Funds OrbiMed Advisors Samsara BioCapital	undisclosed